The Strange and Twisted Tale of Hydroxychloroquine

This is yet another study flawed in the same way most HCL studies are flawed: they use hospitalization as criteria for inclusion in the study. Waiting for hospitalization, indeed any delay, is an error.

The original (and current) protocols for hydroxychloroquine mandate HCL+ZINC+AZITHROMYCIN EARLY (within the first few days of symptoms). Early aggressive treatment stops the virus (and minimizes bacterial infection that otherwise might follow), whereas waiting until the lungs are severely damaged and clogged results in failure.

In this study, as in almost all others, doctors waited until patients were in severe respiratory distress and had to be admitted to a hospital. Once admitted, patients waited even longer before they were admitted to the study and given treatment. From the article:

>"Design, Setting, and Participants This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020 ..."<

There is a difference between treatment within 1-3 days of occurrence and treatment 1-3 weeks after occurrence.